IPHA
Innate Pharma S.A.
There isn't enough reported data to score IPHA yet.
IPHA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IPHA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
IPHA PE Valuation
IPHA has no meaningful PE right now: it lost money over the past year.
IPHA Forward outlook
There aren't enough analyst estimates for IPHA to show an outlook.
IPHA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.61 | +$0.07 |
| Q2 2025 | -$0.61 | -$0.14 |
| Q4 2024 | -$0.68 | -$0.58 |
| Q2 2024 | -$0.47 | +$0.41 |
| Q4 2023 | -$0.10 | +$0.71 |
| Q2 2023 | -$0.88 | -$0.57 |
| Q4 2022 | -$0.81 | -$0.08 |
IPHA is still losing money, but less than at its worst: $0.61 per share over the past year, against $0.88 at its worst in mid-2023.
IPHA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.5M | -35% |
| Q4 2025 | $4.6M | -47% |
| Q2 2025 | $5.4M | -61% |
| Q4 2024 | $8.6M | -64% |
| Q2 2024 | $13.7M | -69% |
| Q4 2023 | $23.8M | +77% |
| Q2 2023 | $44.7M | -12% |
| Q4 2022 | $13.4M | +34% |
IPHA's revenue has slid since its 2018 peak: $4M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -692% | -479 points |
| Q4 2025 | -690% | -632 points |
| Q2 2025 | -523% | -522 points |
| Q4 2024 | -325% | +221 points |
| Q2 2024 | -213% | -232 points |
| Q4 2023 | -57% | +191 points |
| Q2 2023 | -1% | +161 points |
| Q4 2022 | -545% | -481 points |
IPHA's operating margin was −692% last quarter, down 479 points from the same quarter a year ago, near the bottom of its range since 2012.
IPHA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$23.8M | +$10.9M |
| Q4 2025 | -$24.1M | -$12.9M |
| Q2 2025 | -$34.7M | -1234% |
| Q4 2024 | -$11.2M | +$12.3M |
| Q2 2024 | $3.1M | +$16.1M |
| Q4 2023 | -$23.5M | -$719.9K |
| Q2 2023 | -$13.1M | -1575% |
| Q4 2022 | -$22.8M | +$8.3M |
IPHA has burned cash in most quarters: −$94M over the past year, against −$56M the year before.
IPHA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +4.2M shares |
| 1 year | +16% | +13M shares |
| 3 years | +19% | +14.9M shares |
| 5 years | +74% | +40M shares |
| Available history | +147% | +55.9M shares |
IPHA has 94M diluted shares, up 16% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
| Q4 2017 | — |
IPHA Net Leverage
IPHA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IPHA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 8.2 | Oversold |
IPHA's weekly RSI is 42 (neutral) and its Stochastic is 8 (oversold).
IPHA PE vs Healthcare Sector
IPHA has no meaningful PE right now: it lost money over the past year.
IPHA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.53 | 2.6% below |
| 20 week MA | $1.77 | 16% below |
| 50 week MA | $1.71 | 13% below |
| 100 week MA | $1.85 | 19% below |
| 200 week MA | $2.23 | 33% below |
IPHA is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
IPHA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.50 | $4.27 | -34% |
| 2021 | $4.27 | $5.17 | +21% |
| 2022 | $5.17 | $2.81 | -46% |
| 2023 | $2.81 | $2.80 | -0.4% |
| 2024 | $2.80 | $2.11 | -25% |
| 2025 | $2.11 | $1.75 | -17% |
| 2026 YTD | $1.75 | $1.49 | -15% |
IPHA has finished four years in a row lower, and it's down 15% so far in 2026.